RCEL News and Press, Avita Medical Inc. From 11/09/23

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, tod...

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Avita Medical Inc. (RCEL) is expected to report $-0.53 for Q3 2023

2023-10-21 04:10:10 ET Summary Regulatory setbacks for RECELL GO add uncertainty, potentially providing competitors room to maneuver while awaiting FDA approval. Despite the FDA's demand for additional data, AVITA’s balance sheet is fortified with a $40M debt infusion, exte...

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its...

2023-10-18 09:48:22 ET More on AVITA Medical AVITA Medical Q2 2023 Earnings Call Transcript AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair AVITA's Balancing Act: RECELL System's Promise Amid Market Uncertainties Avita Medical slips...

Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed $40 million funded at close; $50 million of additional non-dilutive capital available at the Company’s option, based on the achievement of certain revenue thresholds Capita...

2023-10-02 15:34:49 ET More on AVITA Medical AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair AVITA's Balancing Act: RECELL System's Promise Amid Market Uncertainties Seekin...

2023-10-02 14:37:26 ET Shares of regenerative medicines maker Avita Medical (NASDAQ: RCEL) were down more than 27% as of 1 p.m. ET on Monday. The healthcare company released a Securities and Exchange Commission (SEC) filing on Monday detailing that the Food and Drug Administrati...